Bazedoxifene + conjugated estrogens in HT for the prevention of osteoporosis and treatment of vasomotor symptoms associated with the menopause

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 17, 2013, Pages 2407-2420

  Tella, Sri Harsha ^a   Gallagher, John Christopher ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bazedoxifene; BMD; CE; Menopause; Osteoporosis; Vasomotor symptoms

Indexed keywords

ALUMINUM MAGNESIUM HYDROXIDE; ATORVASTATIN; AZITHROMYCIN; BAZEDOXIFENE; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; DIAZEPAM; DIGOXIN; ESTROGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IBUPROFEN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROGESTERONE DERIVATIVE; RALOXIFENE; WARFARIN;

AMENORRHEA; AREA UNDER THE CURVE; BLEEDING; BONE DENSITY; BREAST TENDERNESS; CORONARY ARTERY DISEASE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPAREUNIA; EARLY MENOPAUSE; ENDOMETRIAL THICKNESS; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; ESTROGEN THERAPY; HEART INFARCTION; HORMONAL THERAPY; HOT FLUSH; HUMAN; IC 50; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; LIVER FAILURE; MASTALGIA; MAXIMUM PLASMA CONCENTRATION; MENOPAUSAL SYNDROME; META ANALYSIS (TOPIC); MULTIPLE DRUG DOSE; MUSCLE SPASM; NONHUMAN; PATIENT SATISFACTION; PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA CONCENTRATION-TIME CURVE; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SLEEP DISORDER; SLEEP QUALITY; SPINE FRACTURE; SPOTTING; TIME TO MAXIMUM PLASMA CONCENTRATION; UTERUS BLEEDING; VAGINA ATROPHY; VAGINAL DRYNESS; VAGINITIS; VENOUS THROMBOEMBOLISM;

ANIMALS; ESTROGENS; ESTROGENS, CONJUGATED (USP); FEMALE; HOT FLASHES; HUMANS; INDOLES; MENOPAUSE; OSTEOPOROSIS; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 84887936234     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.844790     Document Type: Review

References (57)

1. Pacifici R. Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis. J Bone Miner Res 1996;11:1043-51
2. Riggs BL, Khosla S, Melton LJ III. A unitary model for involutional osteoporosis: Estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res 1998;13:763-73
3. Hofbauer LC, Kosla S, Dunstan CR, et al. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 2000;15:2-12
4. Shevde NK, Bendixen AC, Dienger KM, Pike JW. Estrogens suppress RANK ligandinduced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. Proc Natl Acad Sci USA 2000;97:7829-34
5. Hedlund LR, Gallagher JC, Meeger C, et al. Change in vertebral shape in spinal osteoporosis. Calcif Tissue Int 1989; 44(3):168-72
6. Greendale GA, Lee NP, Arriola ER. The menopause. Lancet 1999;353(9152): 571-80
7. Gamsjaeger S, Brozek W, Recker R, et al. Transmenopausal changes in trabecular bone quality. J Bone Miner Res 2013; Epub ahead of print
8. Guglielmi G, Scalzo G. Imaging tools transform diagnosis of osteoporosis. Diagn Imaging Eur 2010;26:7-11
9. Santoro N. Symptoms of menopause: Hot flushes. Clin Obstet Gynecol 2008;51(3):539-48
10. Avis ND, Stellato R, Crawford S, et al. Is there a menopausal syndrome? Menopausal status and symptoms across racial/ethnic groups. Soc Sci Med 2001;52:345-56
11. Chlebowski RT, Anderson GL, Gass M, et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 2010; 304(15):1684-92
12. Heiss G, Wallace R, Anderson GL, et al. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 2008; 299(9):1036-45
13. Stovall DW, Utian W, Gass M, et al. The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety. Menopause 2007;14:510-17
14. Davis SR, O'Neill SM, Eden J, et al. Transition from estrogen therapy to raloxifene in postmenopausal women: Effects on treatment satisfaction and the endometrium: A pilot study. Menopause 2004;11:167-75
15. Carranza-Lira S, Gooch AL, Saldivar N, et al. Climacteric symptom control after the addition of low-dose esterified conjugated estrogens to raloxifene standard doses. Int J Fértil Womens Med 2007;52:93-6
16. Miller PD, Chines AA, Christiansen C, et al. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res 2008;23:525-35
17. Silverman SL, Christiansen C, Genant HK, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: Results from a 3-year, randomized, placebo-And active-controlled clinical trial. J Bone Miner Res 2008;23:1923-34
18. Miller CP, Collini MD, Tran BD, et al. Design, synthesis, and preclinical characterization of novel, highly selective indole estrogens. J Med Chem 2001;44: 1654-7
19. Ermer J, McKeand W, Sullivan P, et al. Bazedoxifene acetate dose proportionality in healthy postmenopausal women. Clin Pharmacol Ther 2003;73:46
20. Patat A, McKeand W, Baird-Bellaire S, et al. Absolute/relative bioavailability of bazedoxifene acetate in health postmenopausal women. Clin Pharmacol Ther 2003;73:43
21. Chandrasekaran A, Ermer J, McKeand W, et al. Bazedoxifene acetate metabolic disposition in healthy postmenopausal women. Clin Pharmacol Ther 2003;73:47
22. Lindsay R, Gallagher JC, Kagan R, et al. Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens (BZA/CE) for osteoporosis prevention in at-risk postmenopausal women. Fertil Steril 2009;92:1045-52
23. Pinkerton JV, Utian WH, Constantine GD. Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: A randomized, controlled trial. Menopause 2009;16(6):1116-24
24. Utian WH, Yu H, Bobula J, et al. Bazedoxifene/conjugated estrogens and quality of life in postmenopausal women. Maturitas 2009;63:329-35
25. Pinkerton JV, Pan K, Abraham L, et al. Sleep parameters and health-related quality of life with bazedoxifene/ conjugated estrogens: A randomized trial. Menopause 2013; [Epub ahead of print]
26. Komm BS, Kharode YP, Bodine PV, et al. Bazedoxifene acetate: A selective estrogen receptor modulator with improved selectivity. Endocrinology 2005;146:3999-4008
27. Komm BS, Lyttle CR. Developing a SERM: Stringent preclinical selection criteria leading to an acceptable candidate (WAY-140424) for clinical evaluation. Ann NY Acad Sci 2001;949:317-26
28. Crabtree JS, Peano BJ, Zhang X, et al. Activity of three selective estrogen receptor modulators on hormone dependent responses in the mouse uterus and mammary gland. Mol Cell Endocrinol 2008;287:40-6
29. Kharode Y, Bodine PVN, Miller CP, et al. The pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis prevention. Endocrinology 2008;149:6084-91
30. Peano BJ, Crabtree JS, Komm BS, et al. Effects of various selective estrogen receptor modulators with or without conjugated estrogens on mouse mammary gland. Endocrinology 2009;150:1897-903
31. Archer DF, Lewis V, Carr BR, et al. Bazedoxifene/conjugated estrogens (BZA/ CE): Incidence of uterine bleeding in postmenopausal women. Fertil Steril 2009;92:1039-44
32. Pickar JH, Yeh I-T, Bachmann G, Speroff L. Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy. Fertil Steril 2009;92:1018-24
33. Kagan R, Williams RS, Pan K, et al. A randomized, placebo-And active-controlled trial of bazedoxifene/ conjugated estrogens (BZA/CE) for treatment of moderate to severe vulvar/ vaginal atrophy in postmenopausal women. Menopause 2010;17:281-9
34. Nastri CO, Lara LA, Ferriani RA, et al. Hormone therapy for sexual function in perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2013;6:CD009672
35. Mirkin S, Komm BS, Pan K, et al. Effects of bazedoxifene/conjugated estrogens on endometrial safety and bone in postmenopausal women. Climacteric 2013;16(3):338-46
36. Pinkerton JV, Harvey JA, Pan K, et al. Breast effects of bazedoxifene-conjugated estrogens: A randomized controlled trial. Obstet Gynecol 2013;121(5):959-68
37. Lobo RA, Pinkerton JV, Gass ML, et al. Evaluation of bazedoxifene/ conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. Fertil Steril 2009;92(3):1025-38
38. Clarkson TB, Ethun KF, Pajewski NM. Effects of bazedoxifene, conjugated equine estrogens, and a tissue-selective estrogen complex containing both bazedoxifene and conjugated equine estrogens on cerebral artery atherosclerosis in postmenopausal monkeys. Menopause 2013; Epub ahead of print
39. Clarkson TB, Ethun KF, Chen H. Effects of bazedoxifene alone and with conjugated equine estrogens on coronary and peripheral artery atherosclerosis in postmenopausal monkeys. Menopause 2013;20(3):274-81
40. Palacios S, de Villiers TJ, Nardone Fde C. Assessment of the safety of long-Term bazedoxifene treatment on the reproductive tract in postmenopausal women with osteoporosis: Results of a 7-year, randomized, placebo-controlled, phase 3 study. Maturitas 2013;76(1):81-7
41. Wattanakumtornkul S, Chichareon S, Geater A, et al. Compliance with hormone replacement therapy at Songklanagarind Hospital. J Obstet Gynaecol Res 2003;29:380-7
42. Manonai J, Theppisai U, Suchartwatnachai C, et al. Compliance with hormone replacement therapy in Thai women. Maturitas 2003;44:201-5
43. Archer DF, Dorin M, Lewis V, et al. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding. Fertil Steril 2001;75:1080-7
44. Stovall DW. Aprela, a single tablet formulation of bazedoxifene and conjugated equine estrogens (Premarin) for the potential treatment of menopausal symptoms. Curr Opin Investig Drugs 2010;11(4):464-71
45. North American Menopause Society. Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010; 17:25-54
46. Loprinzi CL, Sloan J, Stearns V, et al. Newer antidepressants and gabapentin for hot flashes: An individual patient pooled analysis. J Clin Oncol 2009;27: 2831-7
47. Pandya KJ, Raubertas RF, Flynn PJ, et al. Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: A University of Rochester Cancer Center Community Clinical Oncology Program study. Ann Intern Med 2000;132:788-93
48. Nelson HD, Vesco KK, Haney E, et al. Nonhormonal therapies for menopausal hot flashes: Systematic review and meta-Analysis. JAMA 2006;295:2057-71
49. North American Menopause Society. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause 2007;14:355-69
50. Utian WH, Archer DF, Bachmann GH, et al. Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. Menopause 2008;15:584-602
51. Pluchino N, Cubeddu A, Giannini A, et al. Progestogens and brain: An update. Maturitas 2009;62:349-55
52. Bitzer J. Progesterone, progestogens and psychosomatic health of the climacteric woman. Maturitas 2009;62:330-3
53. Goletiani NV, Keith DR, Gorsky SJ. Progesterone: Review of safety for clinical studies. Exp Clin Psychopharmacol 2007; 15:427-44
54. Greenspan SL, Harris ST, Bone H, et al. Bisphosphonates: Safety and efficacy in the treatment and prevention of osteoporosis. Am Fam Physician 2000; 61(9):2731-6
55. Stefanick ML, Anderson GL, Margolis KL, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006;295:1647-57
56. Colditz GA, Rosner B. Cumulative risk of breast cancer to age 70 years according to risk factor status: Data from the Nurses' Health Study. Am J Epidemiol 2000;152:950-64
57. Kharode Y, Bodine PVN, Miller CP, et al. The pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis prevention. Endocrinology 2008;149:6084-91